Q-omics provides the consensus-scored NAMPTP3 profile across patient tissues and cancer cell-line models. NAMPTP3 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, NAMPTP3 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, NAMPTP3 RNA expression shows 4,381 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight UCS, HNSC, and SKCM as cancer lineages where NAMPTP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAMPTP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAMPTP3 survival associations across molecular data types. NAMPTP3 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAMPTP3 RNA expression–survival associations across cancer types. High NAMPTP3 expression shows unfavorable associations in UCS, PAAD, SKCM, THYM, LGG and KIRP. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify UCS as the clearest survival context for NAMPTP3 RNA expression.
This table summarizes NAMPTP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NAMPTP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAMPTP3 shows lower tumor expression in LIHC and KICH and higher tumor expression in HNSC, COAD and KIRP. The HNSC box plot shows higher NAMPTP3 RNA expression in tumor versus normal tissue (log2 FC = +0.093, t-test p = .039).
This table shows molecular features associated with NAMPTP3 in patient tissues and cancer cell lines. In patient samples, NAMPTP3 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
